Servicio de Urgencias, Hospital General Universitario Dr. Balmis, Alicante, Spain; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
Servicio de Urgencias, Hospital General Universitario Dr. Balmis, Alicante, Spain.
Rev Clin Esp (Barc). 2023 Apr;223(4):244-249. doi: 10.1016/j.rceng.2023.03.001. Epub 2023 Mar 2.
The COVID-19-12O-score has been validated to determine the risk of respiratory failure in patients hospitalized for COVID-19. Our study aims to assess whether the score is effective in patients with SARS-CoV-2 pneumonia discharged from a hospital emergency department (HED) to predict readmission and revisit.
Retrospective cohort of patients with SARS-CoV-2 pneumonia discharged consecutively from an HUS of a tertiary hospital, from January 7 to February 17, 2021, where we applied the COVID-19-12O -score, with a cut-off point of 9 points to define the risk of admission or revisit. The primary outcome variable was revisit with or without hospital readmission after 30 days of discharge from HUS.
We included 77 patients, with a median age of 59 years, 63.6% men and Charlson index of 2. 9.1% had an emergency room revisit and 15.3% had a deferred hospital admission. The relative risk (RR) for emergency journal was 0.46 (0.04-4.62, 95% CI, p=0.452), and the RR for hospital readmission was 6.88 (1.20-39.49, 95% CI, p<0.005).
The COVID-19-12O -score is effective in determining the risk of hospital readmission in patients discharged from HED with SARS-CoV-2 pneumonia, but is not useful for assessing the risk of revisit.
COVID-19-12O 评分已被验证可用于确定因 COVID-19 住院的患者发生呼吸衰竭的风险。本研究旨在评估该评分在因 SARS-CoV-2 肺炎从医院急诊科(HED)出院的患者中预测再入院和再就诊的有效性。
回顾性队列研究纳入了 2021 年 1 月 7 日至 2 月 17 日期间连续从一家三级医院 HUS 出院的 SARS-CoV-2 肺炎患者,我们应用 COVID-19-12O 评分,以 9 分为切点定义入院或再就诊的风险。主要结局变量是出院后 30 天内是否因 SARS-CoV-2 肺炎再就诊或再次入院。
共纳入 77 例患者,中位年龄为 59 岁,63.6%为男性,Charlson 指数为 2.9。1.7%的患者急诊再就诊,15.3%的患者延迟入院。急诊就诊的相对风险(RR)为 0.46(0.04-4.62,95%CI,p=0.452),医院再入院的 RR 为 6.88(1.20-39.49,95%CI,p<0.005)。
COVID-19-12O 评分可有效预测因 SARS-CoV-2 肺炎从 HED 出院患者的再入院风险,但对评估再就诊风险无效。